Dave is a life sciences industry veteran with an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings. Most recently, he was president and chief executive officer of Omniome, where he guided and scaled the DNA sequencing company from the early technology development stage through the delivery of its beta prototype leading to its sale to PacBio in 2021. Prior to Omniome, Dave served as the president and chief operating officer of Ariosa Diagnostics, a global diagnostics company focused on using cell-free DNA in non-invasive prenatal testing that was acquired by Roche in 2014. Post-acquisition, Dave served as lifecycle leader, site head, and a core member of the Roche Sequencing Solutions leadership team. He has also held positions at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceuticals Sciences.

Samuel joined ClearNote Health at its inception and has co-authored many of the research papers we have published about our epigenomics technology platform and our DNA-based 5-hydroxymethylcytosine (5hmC) biomarker. For more than 20 years, he has held leadership positions in genomics and molecular diagnostic development at companies including Celera, Genomic Health, Quanticel Pharmaceuticals (now part of Celgene), and Impact Genomics/Lexent Bio which he co-founded and is now a part of Foundation Medicine. Samuel has also served on the faculty at the J. Craig Venter Institute, Scripps Translational Science Institute and Scripps Research Institute. He holds degrees from the University of Bristol and the University of Leeds in the United Kingdom.

Kelly has 20 years of experience as an AP/CP boarded practicing pathologist and hematopathologist, specializing in the diagnosis of blood cancers. She was a senior clinical investigator for an NIH-funded research center investigating circulating tumor cells in people with cancer. She co-founded Epic Sciences, where she was the initial lab director and led CLIA/CAP certification for a liquid biopsy assay using circulating tumor cells. Kelly holds degrees from Yale University and George Washington University School of Medicine.

Jim has more than 20 years of experience directing the global commercialization of molecular diagnostics and cancer therapeutics in oncology at companies including Searle/Pfizer and Genomic Health/Exact Sciences. He was chief commercial officer and global market lead for Oncotype DX breast, colorectal and prostate cancer products. In his more than two decades in the industry, he has developed a breadth of expertise in sales, marketing, product development, medical affairs and reimbursement strategy. Working and living internationally, Vaughn launched both diagnostic and therapeutic oncology, hematology, and urology products. Jim earned his MBA from the Kellogg School of Business at Northwestern and holds a BS in Pharmacy from Creighton University.

Wayne has more than 20 years of experience in bioinformatics, genomics and drug discovery. He cofounded Atreca and Innectus, and held leadership positions at Renovis (now part of Evotec), Ceres, and Incyte Pharmaceuticals. Wayne has been granted US patents and has co-authored multiple peer-reviewed publications. He holds degrees from Stanford University, Princeton University, and University of Minnesota.

Anna has over a decade of experience in next-generation sequencing assay workflows and has worked as a senior scientist at ClearNote Health. Previously, at Genomic Health, she led the technical development of blood-based liquid biopsy assay. Anna holds a PhD in Molecular Oncology from the University of Oslo, Norway in collaboration with Stanford where she spent most of her time in the optimization of array CGH. She holds a Master’s in Medical Biotechnology from the University of Modena School of Medicine, Italy.

Danielle is an accomplished health policy strategist who has led teams across government affairs, market access, and reimbursement functions for over 25 years. Her extensive subject matter expertise guided innovative payment reforms across precision medicine diagnostics during her tenure at Sanofi Aventis, Genomic Health, Adaptive Biotechnologies, and Hologic. A principal voice in diagnostic health policy, Danielle has chaired the Coalition for 21st Century Medicine Reimbursement and Policy Workgroup, the California Healthcare Institute Diagnostic Workgroup, and participated in several CPT working groups for the American Medical Association. A member of leading federal and state diagnostic trade associations, Danielle earned her Master’s in Health Administration at Florida International University and a Bachelor of Science in Marketing from the University of Florida.

Eric has more than 20 years of experience directing IT for life sciences companies including Response Genetics Inc., Cypress Bioscience Inc., Suneva Medical Inc., and Orchestra Therapeutics Inc. He holds a B.S. in Business Administration/Information and Decision Systems from San Diego State University. He also served in the U.S. Marine Corps.

Shimul has served as a clinical laboratory director in multiple laboratories including Rady Children’s Institute for Genomic Medicine (RCIGM), Illumina Inc. and Quest Diagnostics. He has dedicated his career to implementing new genomic technologies to improve patient care and outcomes. He is a board-certified clinical molecular geneticist and licensed as a laboratory director in California, Florida and New York. He has authored over 30 peer-reviewed publications.